All In Biotech

Drug Trial Radar · NCT00806819

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy

Last checked: Nov 20, 2026Latest source record: Feb 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 718 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

718

Actual

Start

Dec 2008

Primary completion

Jun 2011

Study completion Dec 2015

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Dec 11, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent NSCLC. Safety information about BIBF1120/pemetrexed will be obtained.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • Nintedanib (BIBF1120)Drug

    starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.

  • PemetrexedDrug

    500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.

  • pemetrexedDrug

    500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.

  • B12Drug

    1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed

  • dexamethasone (or corticosteroid equivalent)Drug

    4 mg PO bid the day before, the day of and the day after each pemetrexed infusion

  • placeboDrug

    starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.

  • dexamethasone (or corticosteroid equivalent)Drug

    4 mg PO bid the day before, the day of and the day after each pemetrexed infusion

  • B12Drug

    1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed

  • Folic AcidDrug

    400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.

  • B12Drug

    1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed

  • dexamethasone (or corticosteroid equivalent)Drug

    4 mg PO bid the day before, the day of and the day after each pemetrexed infusion

  • Folic AcidDrug

    400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.

  • placeboDrug

    starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.

  • Folic AcidDrug

    400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.

  • Nintedanib (BIBF1120)Drug

    starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.

  • PemetrexedDrug

    500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as Assessed by Central Independent ReviewTime frame: From randomisation until cut-off date 9 July 2012

Locations

163 sites in 32 countries. Site status is shown where the registry gives one.

  • Boehringer Ingelheim Investigational Site

    Downy, California

  • Boehringer Ingelheim Investigational Site

    Fountain Valley, California

  • Boehringer Ingelheim Investigational Site

    Fullerton, California

  • Boehringer Ingelheim Investigational Site

    Long Beach, California

  • Boehringer Ingelheim Investigational Site

    Meriden, Connecticut

  • Boehringer Ingelheim Investigational Site

    Aventura, Florida

  • Boehringer Ingelheim Investigational Site

    Boynton Beach, Florida

  • Boehringer Ingelheim Investigational Site

    Jacksonville, Florida

  • Boehringer Ingelheim Investigational Site

    Miami, Florida

  • Boehringer Ingelheim Investigational Site

    New Port Richey, Florida

  • Boehringer Ingelheim Investigational Site

    Port Saint Lucie, Florida

  • Boehringer Ingelheim Investigational Site

    Stuart, Florida

  • Boehringer Ingelheim Investigational Site

    Galesburg, Illinois

  • Boehringer Ingelheim Investigational Site

    Skokie, Illinois

  • Boehringer Ingelheim Investigational Site

    Indianapolis, Indiana

  • Boehringer Ingelheim Investigational Site

    New Albany, Indiana

  • Boehringer Ingelheim Investigational Site

    Witchita, Kansas

  • Boehringer Ingelheim Investigational Site

    Ashland, Kentucky

  • Boehringer Ingelheim Investigational Site

    Louisville, Kentucky

  • Boehringer Ingelheim Investigational Site

    Burlington, Massachusetts

  • Boehringer Ingelheim Investigational Site

    Springfield, Massachusetts

  • Boehringer Ingelheim Investigational Site

    Saint Louis Park, Minnesota

  • Boehringer Ingelheim Investigational Site

    Grand Island, Nebraska

  • Boehringer Ingelheim Investigational Site

    Farmington, New Mexico

  • Boehringer Ingelheim Investigational Site

    Dunkirk, New York

  • Boehringer Ingelheim Investigational Site

    Goshen, New York

  • Boehringer Ingelheim Investigational Site

    Lake Success, New York

  • Boehringer Ingelheim Investigational Site

    Nyack, New York

  • Boehringer Ingelheim Investigational Site

    Asheville, North Carolina

  • Boehringer Ingelheim Investigational Site

    Canton, Ohio

  • Boehringer Ingelheim Investigational Site

    Sandusky, Ohio

  • Boehringer Ingelheim Investigational Site

    Ephrata, Pennsylvania

  • Boehringer Ingelheim Investigational Site

    Langhorne, Pennsylvania

  • Boehringer Ingelheim Investigational Site

    Philadelphia, Pennsylvania

  • Boehringer Ingelheim Investigational Site

    Germantown, Tennessee

  • Boehringer Ingelheim Investigational Site

    Amarillo, Texas

  • Boehringer Ingelheim Investigational Site

    Seattle, Washington

  • Boehringer Ingelheim Investigational Site

    Spokane, Washington

  • Boehringer Ingelheim Investigational Site

    Madison, Wisconsin

  • Boehringer Ingelheim Investigational Site

    Milwaukee, Wisconsin

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.